Friday, July 10, 2026

pharma · Mantle Cell Lymphoma · Colon cancer

Telethon Foundation

Fondazione Telethon ETS is a pharma organization headquartered in EU. Primary therapeutic focus areas include Mantle Cell Lymphoma, Colon cancer, colorectal cancer, NSCLC non-small cell lung cancer, Follicular lymphoma.

roma, IT HQ
1990 Founded
343 Employees
EMA registrant Type
Company details
Status
Public
HQ
roma, IT
Founded
1990
Employees
343
Programs
162
Drugs
285
Patents
0
Clinical program

EMN20

Phase 3 · small molecule · PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

EMN20 for PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT is a Phase 3 program (small_molecule) at Fondazione Telethon ETS with 1 ClinicalTrials.gov record(s).

← All Fondazione Telethon ETS projects Phase 3 small molecule active

Internal code EMN20

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Fondazione Telethon ETS
Phase
Phase 3
Modality
small_molecule
Indication
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT
Status
active
Trials
1